|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kitamura H, Okudela K, Yazawa T, Sato H
and Shimoyamada H: Cancer stem cell: Implications in cancer biology
and therapy with special reference to lung cancer. Lung Cancer.
66:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szotek PP, Pieretti-Vanmarcke R, Masiakos
PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F,
Maclaughlin DT and Donahoe PK: Ovarian cancer side population
defines cells with stem cell-like characteristics and Mullerian
Inhibiting Substance responsiveness. Proc Natl Acad Sci USA.
103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H, et al: The ABC transporter Bcrp1/ABCG2 is expressed in
a wide variety of stem cells and is a molecular determinant of the
side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang G, Wang Z, Luo W, Jiao H, Wu J and
Jiang C: Expression of potential cancer stem cell marker ABCG2 is
associated with malignant behaviors of hepatocellular carcinoma.
Gastroenterol Res Pract. 2013:7825812013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noguchi K, Katayama K and Sugimoto Y:
Human ABC transporter ABCG2/BCRP expression in chemoresistance:
Basic and clinical perspectives for molecular cancer therapeutics.
Pharm Genomics Pers Med. 7:53–64. 2014.
|
|
9
|
Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH,
Cheng HW, Li YQ, Ambudkar SV and Hsu SC: Overexpression of
ATP-binding cassette transporter ABCG2 as a potential mechanism of
acquired resistance to vemurafenib in BRAF(V600E) mutant cancer
cells. Biochem Pharmacol. 85:325–334. 2013. View Article : Google Scholar :
|
|
10
|
Nakanishi T and Ross DD: Breast cancer
resistance protein (BCRP/ABCG2): Its role in multidrug resistance
and regulation of its gene expression. Chin J Cancer. 31:73–99.
2012. View Article : Google Scholar
|
|
11
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar :
|
|
12
|
Oda K, Nishimura T, Higuchi K, Ishido N,
Ochi K, Iizasa H, Sai Y, Tomi M and Nakashima E: Estrogen receptor
α induction by mitoxantrone increases Abcg2 expression in placental
trophoblast cells. J Pharm Sci. 102:3364–3372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen S, Zhang M, Xing L, Wang Y, Xiao Y
and Wu Y: HIF-1α contributes to proliferation and invasiveness of
neuroblastoma cells via SHH signaling. PLoS One. 10:e01211152015.
View Article : Google Scholar
|
|
14
|
Wan J, Chai H, Yu Z, Ge W, Kang N, Xia W
and Che Y: HIF-1α effects on angiogenic potential in human small
cell lung carcinoma. J Exp Clin Cancer Res. 30:772011. View Article : Google Scholar
|
|
15
|
Thomas R and Kim MH: HIF-1 alpha: A key
survival factor for serum-deprived prostate cancer cells. Prostate.
68:1405–1415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J: Pharmacology of oleanolic acid and
ursolic acid. J Ethnopharmacol. 49:57–68. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang X, Yan L, Xu L and Gao J: Comparative
study on the hepatoprotective and anti-oxidation effects of
oleanolic acid, ursolic acid and asiatic acid. Lishizhen Med
Materia Med Res. 21:pp. 2824–2827. 2012, http://en.cnki.com.cn/Article_en/CJFDTOTAL-SZGY201011046.htm.
|
|
18
|
Ikeda Y, Murakami A and Ohigashi H:
Ursolic acid: An anti- and pro-inflammatory triterpenoid. Mol Nutr
Food Res. 52:26–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martin-Aragón S, de las Heras B,
Sanchez-Reus MI and Benedi J: Pharmacological modification of
endogenous antioxidant enzymes by ursolic acid on
tetrachloride-induced liver damage in rats and primary cultures of
rat hepatocytes. Exp Toxicol Pathol. 53:199–206. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Wang W, Qian L, Zhang Q, Lai D
and Qi C: Ursolic acid inhibits the proliferation of human ovarian
cancer stem-like cells through epithelial-mesenchymal transition.
Oncol Rep. 34:2375–2384. 2015.PubMed/NCBI
|
|
21
|
Lim JJ, Yang K, Taylor-Harding B,
Wiedemeyer WR and Buckanovich RJ: VEGFR3 inhibition chemosensitizes
ovarian cancer stemlike cells through down-regulation of BRCA1 and
BRCA2. Neoplasia. 16:343–353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang R, Wang J, Zhong Y, Liu Y, Stokke T,
Trope CG, Nesland JM and Suo Z: Mitochondrial DNA deficiency in
ovarian cancer cells and cancer stem cell-like properties.
Anticancer Res. 35:3743–3753. 2015.PubMed/NCBI
|
|
23
|
Ruiz I, Martín-Arruti M, Lopez-Lopez E and
Garcia-Orad A: Lack of association between deficient mismatch
repair expression and outcome in endometrial carcinomas of the
endometrioid type. Gynecol Oncol. 134:20–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hiraga T, Ito S and Nakamura H: Side
population in MDA-MB-231 human breast cancer cells exhibits cancer
stem cell-like properties without higher bone-metastatic potential.
Oncol Rep. 25:289–296. 2011.
|
|
25
|
Kim RJ and Nam JS: OCT4 expression
enhances features of cancer stem cells in a mouse model of breast
cancer. Lab Anim Res. 27:147–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gazda LS, Martis PC, Laramore MA, Bautista
MA, Dudley A, Vinerean HV and Smith BH: Treatment of
agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+)
cells with tumor-initiating capability. Cancer Biol Ther.
14:1147–1157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Silva IA, Bai S, McLean K, Yang K,
Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds
RK, et al: Aldehyde dehydrogenase in combination with CD133 defines
angiogenic ovarian cancer stem cells that portend poor patient
survival. Cancer Res. 71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim
SW and Kim YT: MicroRNA profiling of a CD133(+) spheroid-forming
subpopulation of the OVCAR3 human ovarian cancer cell line. BMC Med
Genomics. 5:182012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casagrande F, Cocco E, Bellone S, Richter
CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D,
Azodi M, et al: Eradication of chemotherapy-resistant
CD44+ human ovarian cancer stem cells in mice by
intraperitoneal administration of Clostridium perfringens
enterotoxin. Cancer. 117:5519–5528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelialmesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wenger RH: Cellular adaptation to hypoxia:
O2-sensing protein hydroxylases, hypoxia-inducible
transcription factors, and O2-regulated gene expression.
FASEB J. 16:1151–1162. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mathieu J, Zhang Z, Zhou W, Wang AJ,
Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, et al:
HIF induces human embryonic stem cell markers in cancer cells.
Cancer Res. 71:4640–4652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jubb AM, Buffa FM and Harris AL:
Assessment of tumour hypoxia for prediction of response to therapy
and cancer prognosis. J Cell Mol Med. 14:18–29. 2010. View Article : Google Scholar
|
|
34
|
Milosevic M, Warde P, Ménard C, Chung P,
Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M,
et al: Tumor hypoxia predicts biochemical failure following
radiotherapy for clinically localized prostate cancer. Clin Cancer
Res. 18:2108–2114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Fan Y, Qi Y, Liu D, Wu K, Wen F
and Zhao S: Side population cells separated from A549 lung cancer
cell line possess cancer stem cell-like properties and inhibition
of autophagy potentiates the cytotoxic effect of cisplatin. Oncol
Rep. 34:929–935. 2015.PubMed/NCBI
|
|
36
|
Xie ZY, Lv K, Xiong Y and Guo WH:
ABCG2-meditated multidrug resistance and tumor-initiating capacity
of side population cells from colon cancer. Oncol Res Treat.
37:666–668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warrier S, Pavanram P, Raina D and Arvind
M: Study of chemo-resistant CD133+ cancer stem cells from human
glioblastoma cell line U138MG using multiple assays. Cell Biol Int.
36:1137–1143. 2012. View Article : Google Scholar
|
|
38
|
Oh PS, Patel VB, Sanders MA, Kanwar SS, Yu
Y, Nautiyal J, Patel BB and Majumdar AP: Schlafen-3 decreases
cancer stem cell marker expression and autocrine/juxtacrine
signaling in FOLFOX-resistant colon cancer cells. Am J Physiol
Gastrointest Liver Physiol. 301:G347–G355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM,
Kim MS and Park JW: Inhibitory effect of YC-1 on the hypoxic
induction of erythropoietin and vascular endothelial growth factor
in Hep3B cells. Biochem Pharmacol. 61:947–954. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng Y, Li W, Liu Y, Cheng HC, Ma J and
Qiu L: YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer
cells by targeting EGFR in vitro and in vivo under normoxic
condition. Chin J Cancer. 31:248–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu
F, Ke S, Pan B, Shen Q, Sun H, et al: YC-1 enhances the anti-tumor
activity of sorafenib through inhibition of signal transducer and
activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Mol Cancer. 13:72014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhong H, Chiles K, Feldser D, Laughner E,
Hanrahan C, Georgescu MM, Simons JW and Semenza GL: Modulation of
hypoxia-inducible factor 1alpha expression by the epidermal growth
factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human
prostate cancer cells: Implications for tumor angiogenesis and
therapeutics. Cancer Res. 60:1541–1545. 2000.PubMed/NCBI
|
|
43
|
Mazure NM, Chen EY, Laderoute KR and
Giaccia AJ: Induction of vascular endothelial growth factor by
hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt
signaling pathway in Ha-ras-transformed cells through a hypoxia
inducible factor-1 transcriptional element. Blood. 90:3322–3331.
1997.PubMed/NCBI
|
|
44
|
Bleau AM, Hambardzumyan D, Ozawa T,
Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt
pathway regulates the side population phenotype and ABCG2 activity
in glioma tumor stem-like cells. Cell Stem Cell. 4:226–235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kilic-Eren M, Boylu T and Tabor V:
Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation
and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for
apoptosis. Cancer Cell Int. 13:362013. View Article : Google Scholar
|
|
46
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Uchida N, Buck DW, He D, Reitsma MJ, Masek
M, Phan TV, Tsukamoto AS, Gage FH and Weissman IL: Direct isolation
of human central nervous system stem cells. Proc Natl Acad Sci USA.
97:14720–14725. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim CF, Jackson EL, Woolfenden AE,
Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT and Jacks T:
Identification of bronchioalveolar stem cells in normal lung and
lung cancer. Cell. 121:823–835. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reynolds BA and Weiss S: Clonal and
population analyses demonstrate that an EGF-responsive mammalian
embryonic CNS precursor is a stem cell. Dev Biol. 175:1–13. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang L, Mezencev R, Bowen NJ, Matyunina LV
and McDonald JF: Isolation and characterization of stem-like cells
from a human ovarian cancer cell line. Mol Cell Biochem.
363:257–268. 2012. View Article : Google Scholar
|
|
53
|
Soriţău O, Tomuleasa CI, Páll E, Virág P,
Fischer-Fodor E, Foris V, Barbos O, Tatomir C, Kacsó G and Irimie
A: Enhanced chemoresistance and tumor sphere formation as a
laboratory model for peritoneal micrometastasis in epithelial
ovarian cancer. Rom J Morphol Embryol. 51:259–264. 2010.
|
|
54
|
Frelet A and Klein M: Insight in
eukaryotic ABC transporter function by mutation analysis. FEBS
Lett. 580:1064–1084. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Adamski J, Price A, Dive C and Makin G:
Hypoxia-induced cytotoxic drug resistance in osteosarcoma is
independent of HIF-1Alpha. PLoS One. 8:e653042013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xiang L, Liu ZH, Huan Q, Su P, Du GJ, Wang
Y, Gao P and Zhou GY: Hypoxia-inducible factor-2a is associated
with ABCG2 expression, histology-grade and Ki67 expression in
breast invasive ductal carcinoma. Diagn Pathol. 7:322012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen J, Ding Z, Peng Y, Pan F, Li J, Zou
L, Zhang Y and Liang H: HIF-1α inhibition reverses multidrug
resistance in colon cancer cells via downregulation of
MDR1/P-glycoprotein. PLoS One. 9:e988822014. View Article : Google Scholar
|
|
58
|
Méndez O, Zavadil J, Esencay M, Lukyanov
Y, Santovasi D, Wang SC, Newcomb EW and Zagzag D: Knock down of
HIF-1alpha in glioma cells reduces migration in vitro and invasion
in vivo and impairs their ability to form tumor spheres. Mol
Cancer. 9:1332010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Manohar SM, Padgaonkar AA, Jalota-Badhwar
A, Sonawane V, Rathos MJ, Kumar S and Joshi KS: A novel inhibitor
of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway
and inhibits growth of prostate cancer cells. BMC Cancer.
11:3382011. View Article : Google Scholar
|
|
61
|
Befani CD, Vlachostergios PJ, Hatzidaki E,
Patrikidou A, Bonanou S, Simos G, Papandreou CN and Liakos P:
Bortezomib represses HIF-1α protein expression and nuclear
accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in
prostate cancer cells. J Mol Med Berl. 90:45–54. 2012. View Article : Google Scholar
|
|
62
|
Chen Y, Wang BC and Xiao Y: PI3K: A
potential therapeutic target for cancer. J Cell Physiol.
227:2818–2821. 2012. View Article : Google Scholar
|
|
63
|
Fulda S: The PI3K/Akt/mTOR pathway as
therapeutic target in neuroblastoma. Curr Cancer Drug Targets.
9:729–737. 2009. View Article : Google Scholar : PubMed/NCBI
|
